Blood Cancer Journal (Jan 2023)
Extreme body mass index and survival in newly diagnosed multiple myeloma patients
- Urvi A. Shah,
- Karissa Whiting,
- Sean Devlin,
- Rachel Ershler,
- Bindu Kanapuru,
- David J. Lee,
- Sabrin Tahri,
- Thomas Gwise,
- Even H. Rustad,
- Sham Mailankody,
- Alexander M. Lesokhin,
- Dickran Kazandjian,
- Francesco Maura,
- Daniel Auclair,
- Brenda M. Birmann,
- Saad Z. Usmani,
- Nicole Gormley,
- Catherine R. Marinac,
- Ola Landgren
Affiliations
- Urvi A. Shah
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Karissa Whiting
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York
- Sean Devlin
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York
- Rachel Ershler
- Division of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food, and Drug Administration
- Bindu Kanapuru
- Division of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food, and Drug Administration
- David J. Lee
- Department of Medicine, Massachusetts General Hospital
- Sabrin Tahri
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Thomas Gwise
- Division of Biometrics IX, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- Even H. Rustad
- Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet
- Sham Mailankody
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Alexander M. Lesokhin
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Dickran Kazandjian
- Department of Medicine, Sylvester Comprehensive Cancer Center at the University of Miami
- Francesco Maura
- Department of Medicine, Sylvester Comprehensive Cancer Center at the University of Miami
- Daniel Auclair
- Multiple Myeloma Research Foundation
- Brenda M. Birmann
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Saad Z. Usmani
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Nicole Gormley
- Division of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food, and Drug Administration
- Catherine R. Marinac
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Ola Landgren
- Department of Medicine, Sylvester Comprehensive Cancer Center at the University of Miami
- DOI
- https://doi.org/10.1038/s41408-022-00782-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 5
Abstract
No abstracts available.
